Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving T cell therapy for cancer.

Ann M Leen1, Cliona M Rooney, Aaron E Foster

  • 1Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA.

Annual Review of Immunology
|November 30, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating mesothelin as an immunotherapeutic target for endogenous T cells.

Frontiers in immunology·2026
Same author

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026
Same author

Macrophages as gatekeepers of glioma progression.

Molecular therapy. Oncology·2026
Same author

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.

Nature medicine·2026
Same author

Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial.

iScience·2025

Adoptive T cell therapy shows promise for cancer treatment by overcoming tumor immune evasion. Strategies involve genetically modifying T cells or altering the host environment to enhance therapy efficacy.

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Adoptive T cell therapy is effective against opportunistic diseases and some viral cancers.
  • Efficacy is limited in nonviral cancers due to tumor immune evasion mechanisms like antigen downregulation and immunosuppression.
  • Understanding the tumor microenvironment and T cell behavior is crucial for improving therapy.

Purpose of the Study:

  • To review novel strategies for enhancing adoptive T cell therapy in cancer treatment.
  • To discuss methods for overcoming tumor-induced immunosuppression and improving T cell persistence.

Main Methods:

  • Review of current research on T cell modification and host environment manipulation.
  • Analysis of immune evasion mechanisms employed by nonviral tumors.

Related Experiment Videos

  • Discussion of genetic engineering of T cells and host-directed therapies.

    • Main Results:

    • Genetic modification can enhance T cell tumor recognition and resistance to immunosuppression.
    • Modifying the host environment can improve T cell expansion and eliminate inhibitory immune cells.
    • These approaches aim to overcome barriers to effective T cell therapy in cancer.

    Conclusions:

    • Novel strategies involving T cell engineering and host environment modulation hold significant promise for improving adoptive T cell therapy efficacy.
    • Further research in these areas is essential for advancing cancer treatment through T cell-based approaches.